- Home
- WHF vs ALXO Comparison
WHF vs ALXO Comparison
Compare WHF & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WHF | ALXO |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 172.8M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WHF | ALXO |
|---|---|---|
| Price | $7.40 | $0.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $7.83 | $4.60 |
| AVG Volume (30 Days) | 111.2K | ★ 1.3M |
| Earning Date | 11-09-2026 | 11-06-2026 |
| Dividend Yield | ★ 14.18% | N/A |
| EPS Growth | ★ 31.91 | 26.36 |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.38 | N/A |
| P/E Ratio | $16.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.07 | $0.98 |
| 52 Week High | $7.84 | $2.66 |
Technical Indicators
Market Signals| Indicator | WHF | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 61.69 | 23.70 |
| Support Level | $6.85 | N/A |
| Resistance Level | $7.58 | $2.19 |
| Average True Range (ATR) | 0.20 | 0.12 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 82.66 | 3.01 |
Price Performance
Historical ComparisonAbout WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.